Axsome Therapeutics (AXSM) Receivables (2022 - 2026)

Axsome Therapeutics has reported Receivables for 5 years, with the latest figure at $273.2 million in Q1 2026.

• Quarterly Receivables rose 55.06% year-over-year to $273.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.2 million (up 55.06% YoY) and the FY2025 annual result came in at $246.7 million, up 58.63% from the prior year.
• Receivables climbed to $273.2 million in Q1 2026 per AXSM's latest filing, from $246.7 million in the prior quarter.
• Over five years, Receivables peaked at $273.2 million in Q1 2026 and troughed at $16.2 million in Q2 2022.
• A 5-year average of $127.3 million and a median of $117.7 million in 2024 frame the typical range for Receivables.
• The sharpest annual moves came in 2023 and 2024: Receivables surged 413.75% in 2023, then soared 40.4% in 2024.
• Over 5 years, Receivables stood at $37.7 million in 2022, then jumped by 184.68% to $107.3 million in 2023, then jumped by 44.9% to $155.5 million in 2024, then soared by 58.63% to $246.7 million in 2025, then climbed by 10.75% to $273.2 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $273.2 million, $246.7 million, and $196.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.